Lilly Extends Collaboration With Cancer Institute
Lilly completed the CoLucid acquisition in March.
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowEli Lilly and Company (NYSE: LLY) has announced a three-year extension of its collaboration with Dana-Farber Cancer Institute. Scientists from each organization have been working together on various cancer care elements since 2015.
"This collaboration provides an opportunity for scientists and clinicians at a premier cancer center to bring creative new ideas about the underlying science and how this might drive future clinical opportunities for multiple Lilly therapeutic candidates," said Levi Garraway, M.D., Ph.D., senior vice president, global development and medical affairs, Lilly Oncology. "The extension will provide continued funding for initial testing of several such ideas in the lab and in the clinic, which could eventually inform new treatment avenues for cancer patients."
Lilly scientists have been allowed access to Dana-Farber scientists to develop pre-clinical and clinical compounds in Lilly’s pipeline, and Dana-Farber scientists were granted permission to conduct studies on some Lilly compounds. All compounds studied in the collaboration will still be owned by Lilly. Financial terms of the agreement have not been disclosed. To learn more about Lilly’s cancer treatment efforts, click here.